Dux4 controls migration of mesenchymal stem cells through the Cxcr4-Sdf1 axis

Petr Dmitriev1,2,*, Ekaterina Kiseleva2,3,*, Olga Kharchenko2,3, Evgeny Ivashkin2,3, Andrei Pichugin2,3,7, Philippe Dessen4, Thomas Robert4, Frédérique Coppée5, Alexandra Belayew5, Gilles Carnac6, Dalila Laoudj-Chenivesse6, Marc Lipinski1,2, Andrei Vasiliev3, Yegor S. Vassetzky1,2,3

1UMR 8126, Univ. Paris-Sud, CNRS, Institut de Cancérologie Gustave-Roussy, Villejuif, France
2LIA1066 Laboratoire Franco-Russe de Recherches en Oncologie, Villejuif, France
3N.K. Koltzov Institute of Developmental Biology, RAS, Moscow, Russia
4Functional Genomics Unit, Institut de Cancérologie Gustave-Roussy, Villejuif, France
5Laboratory of Molecular Biology, Research Institute for Health Sciences and Technology, University of Mons, Mons, Belgium
6PhyMedExp, University of Montpellier, INSERM U1046, CNRS UMR 9214, Montpellier, France
7Peter the Great St. Petersburg Polytechnic University, St. Petersburg, Russia

*These authors contributed equally to this work

Correspondence to: Yegor S. Vassetzky, email: vassetzky@igr.fr

Keywords: DUX4, CXCR4, SDF1, signalling, migration

Received: April 01, 2016, Accepted: August 10, 2016, Published: August 18, 2016

ABSTRACT

We performed transcriptome profiling of human immortalized myoblasts (MB) transiently expressing double homeobox transcription factor 4 (DUX4) and double homeobox transcription factor 4 centromeric (DUX4c) and identified 114 and 70 genes differentially expressed in DUX4- and DUX4c-transfected myoblasts, respectively. A significant number of differentially expressed genes were involved in inflammation, cellular migration and chemotaxis suggesting a role for DUX4 and DUX4c in these processes. DUX4 but not DUX4c overexpression resulted in upregulation of the CXCR4 (C-X-C motif Receptor 4) and CXCL12 (C-X-C motif ligand 12 also known as SDF1) expression in human immortalized myoblasts. In a Transwell cell migration assay, human bone marrow-derived mesenchymal stem cells (BMSCs) were migrating more efficiently towards human immortalized myoblasts overexpressing DUX4 as compared to controls; the migration efficiency of DUX4-transfected BMSCs was also increased. DUX4c overexpression in myoblasts or in BMSCs had no impact on the rate of BMSC migration. Antibodies against SDF1 and CXCR4 blocked the positive effect of DUX4 overexpression on BMSC migration. We propose that DUX4 controls the cellular migration of mesenchymal stem cells through the CXCR4 receptor.

INTRODUCTION

Human genome harbors 333 genes and pseudogenes with homeobox sequences encoding homeodomain DNA binding motif. Most of homeobox genes are transcription factors of which many are known to play key roles in animal development (for review see [1]). Among all homeobox genes, the double homeobox (DUX) family is one of the most enigmatic. DUX family members numbered from 1 to 5 [2–4] are encoded within tandem repeats of macrosatellite DNA and their multiple polymorphic copies are spread over human genome. Two other members of the DUX family, DUXA [5] and DUXB [6] are single-copy genes encoded on chromosome 19 and 16, respectively.

Double homeobox protein 4 (DUX4) and its nearly identical homologue DUX4 centromeric (DUX4c) are the best known of all DUX proteins (for review see [7]). Multiple copies of DUX4 ORFs reside within 3.3 kb-long macrosatellite repeats on chromosomes 4q35 and 10q26 also called D4Z4 [8, 3]. The copy number of DUX4 ORF may vary from several units to several hundred making it...
cells) are multipotent stem cells capable of differentiation into chondrocytes, osteocytes, adipocytes and, more controversially, to other cell types (for review see [42]). The primary site of MSC localization is bone marrow, although cells with similar properties were also found in other tissues (for review see [43]). In adult organism, MSC are thought to contribute to tissue homeostasis. Tissue damage results in MSC mobilization from bone marrow and their homing to damaged tissue where they either differentiate to replenish damaged cells, stimulate differentiation of the tissue-resident stem cells, stimulate vasculization and control inflammation thus restoring the damage (reviewed in [44]). CXCR4-SDF1 signaling is known to be required for MSC homing and retention to their niche in bone marrow (for review see [43]) and has also been shown to stimulate MSC cell migration in vitro [45, 46]. We have shown that DUX4 overexpression results in upregulation of CXCR4 and SDF1 genes in several cell types and stimulates the migration of BMSC in a CXCR4- and SDF1-dependent manner. Our results thus establish DUX4 as a novel regulator of cell mobility.

**RESULTS**

**Transcriptome profiling of DUX4- and DUX4c-overexpressing human myoblasts**

Several transcriptomic studies have been performed on cells overexpressing DUX4, at the same time its homologue DUX4c is much less studied. We argued that the difference in transcriptome profiles of DUX4 and DUX4c might help us to better understand the functional differences between these two proteins. We thus performed transcriptome profiling of DUX4- and DUX4c-transfected immortalized human myoblasts (MB) at two time points (12 and 24 h) following transfection. Overall, we have identified 130 differentially expressed genes of which 60 genes were differentially expressed only in DUX4-transfected cells, 16 genes only in DUX4c-transfected cells and 54 genes were differentially expressed both in DUX4- and DUX4c-transfected cells (Figure 1). With rare exceptions, all significantly overexpressed DUX4 target genes found in our study were already described previously [12] (Tables 1–4 and Supplementary Table S1). DUX4 is known to induce apoptosis in various cell types including human myoblasts. Indeed, we observed a significant induction of apoptosis in various cell types and validated our data by western blotting and flow cytometry. We observed a significant increase in cell death in DUX4-transfected cells compared to control cells (Figure 2). In addition, CXCR4 is one of the major GPCR receptors controlling the migration of various cell types including leukocytes, HSPC, MSC (reviewed in [41]).

MSC (mesenchymal stem or mesenchymal stromal cells) are multipotent stem cells capable of differentiation...
included inflammation, chemotaxis, metabolism and apoptosis (Figure 2 and Supplementary Table S2). These functional categories have already been attributed to DUX4 target genes in previous transcriptomic studies of genes differentially expressed in DUX4-overexpressing murine C2C12 myoblasts [14], human primary myoblasts [12] and rhabdomyosarcoma cells [47]; furthermore, functional involvement of ectopically expressed DUX4 in certain aspects of cellular metabolism and regulation of apoptosis has been previously demonstrated [13, 14].

Figure 1: Genes differentially expressed 12- and 24 h after the transfection of human immortalized myoblasts (MB) with DUX4 or DUX4c plasmids as compared to empty vector; yellow: no differential expression (-1.5 < FC < 1.5); red: upregulated (FC > 1.5); green: downregulated (FC < -1.5). (A) Genes differentially expressed in both DUX4- and DUX4c-transfected MB; genes upregulated at both 12 h and 24 h time-points are labeled with (A, B and D) respectively; genes upregulated at 12 h but downregulated at 24 h time-points are labeled with C; genes downregulated at both 12 h and 24 h, only at 12 h or 24 h time-points are labeled with (E, F and G) respectively. (B) Genes differentially expressed only in DUX4-transfected MB; genes upregulated at both 12 h and 24 h time-points with the expression level at 12 h higher, equal or lower than at 24 h are labeled with (A, B or C) respectively; genes upregulated only at 12 h or 24 h time-points are labeled with D and E respectively; genes downregulated at both time-points or only at 24 h time-point are labeled with F and G respectively. (C) Genes differentially expressed only in DUX4c-transfected MB; genes upregulated at 12 h or 24 h or downregulated at 12 h or 24 h time-points are labeled with A, C, D and E respectively; genes upregulated at 12 h but downregulated at 24 h time-points are labeled with B.
Table 1: Genes differentially expressed in hIMB cells 12 h after DUX4-plasmid transfection

<table>
<thead>
<tr>
<th>FC</th>
<th>Gene</th>
<th>Description</th>
<th>ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>217.4</td>
<td>ZSCAN4</td>
<td>zinc finger and SCAN domain containing 4</td>
<td>†</td>
</tr>
<tr>
<td>82.3</td>
<td>TRIM43</td>
<td>tripartite motif containing 43</td>
<td>†</td>
</tr>
<tr>
<td>46.0</td>
<td>PRAMEF1</td>
<td>PRAME family member 1</td>
<td>†</td>
</tr>
<tr>
<td>42.8</td>
<td>RFPL2</td>
<td>ret finger protein-like 2</td>
<td>†</td>
</tr>
<tr>
<td>38.1</td>
<td>USP29</td>
<td>ubiquitin specific peptidase 29</td>
<td>†</td>
</tr>
<tr>
<td>38.0</td>
<td>HPX-2</td>
<td>homeobox HPX-2</td>
<td>†</td>
</tr>
<tr>
<td>34.3</td>
<td>LEUTX</td>
<td>leucine twenty homeobox</td>
<td>†</td>
</tr>
<tr>
<td>33.1</td>
<td>RFPL3</td>
<td>ret finger protein-like 3</td>
<td>†</td>
</tr>
<tr>
<td>29.2</td>
<td>TRIM49</td>
<td>tripartite motif containing 49</td>
<td>†</td>
</tr>
<tr>
<td>27.6</td>
<td>MBD3L2</td>
<td>methyl-CpG binding domain protein 3-like 2</td>
<td>†</td>
</tr>
<tr>
<td>26.2</td>
<td>TRIM64</td>
<td>tripartite motif containing 64</td>
<td>†</td>
</tr>
<tr>
<td>25.0</td>
<td>RFPL4B</td>
<td>ret finger protein-like 4B</td>
<td>†</td>
</tr>
<tr>
<td>21.6</td>
<td>SLC34A2</td>
<td>solute carrier family 34 (type II sodium/phosphate contransporter). member 2</td>
<td>†</td>
</tr>
<tr>
<td>18.6</td>
<td>RFPL1</td>
<td>ret finger protein-like 1</td>
<td>†</td>
</tr>
<tr>
<td>15.5</td>
<td>PRAMEF8</td>
<td>PRAME family member 8</td>
<td>†</td>
</tr>
<tr>
<td>13.5</td>
<td>DUX3</td>
<td>double homeobox 3</td>
<td>†</td>
</tr>
<tr>
<td>12.2</td>
<td>PRAMEF9; PRAMEF25; PRAMEF19; PRAMEF22</td>
<td>PRAME family member 9; PRAME family member 25; PRAME family member 19; PRAME family member 22</td>
<td>†</td>
</tr>
<tr>
<td>7.9</td>
<td>FRG2</td>
<td>FSID region gene 2</td>
<td>†</td>
</tr>
<tr>
<td>7.5</td>
<td>CXCL9</td>
<td>chemokine (C-X-C motif) ligand 9</td>
<td>†</td>
</tr>
<tr>
<td>7.0</td>
<td>TRIM51; TRIM51HP</td>
<td>tripartite motif-containing 51; tripartite motif-containing 51H. pseudogene</td>
<td>†</td>
</tr>
<tr>
<td>6.7</td>
<td>MRAF2</td>
<td>melanocortin 2 receptor accessory protein 2</td>
<td>†</td>
</tr>
</tbody>
</table>
* | 6.5 | GC3                       | glucagon                                                                    | †   |
| 6.2  | PRAMEF2                   | PRAME family member 2                                                        | †   |
| 5.5  | FAM90A1                   | family with sequence similarity 90. member A1                               | †   |
| 5.5  | TRIM48                    | tripartite motif containing 48                                               | †   |
| 5.5  | CCDC30                    | coiled-coil domain containing 30                                             | †   |
* | 5.4 | CCL20                     | chemokine (C-C motif) ligand 20                                              | †   |
| 4.9  | DGKE                      | diacylglycerol kinase. epsilon 64kDa                                        | †   |
* | 4.8 | CXCL3                     | chemokine (C-X-C motif) ligand 3                                             | †   |
* | 4.7 | CXCL11                    | chemokine (C-X-C motif) ligand 11                                            | †   |
| 4.5  | CCL3                      | chemokine (C-C motif) ligand 3                                               | †   |
| 4.5  | DHR32                     | dehydrogenase/reductase (SDR family) member 2                               | †   |
* | 4.3 | CXCL1                     | chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity. alpha) | †   |
| 4.1  | PPP4R4                    | protein phosphatase 4. regulatory subunit 4                                 | †   |
* | 4.0 | NR4A3                     | nuclear receptor subfamily 4. group A. member 3                             | †   |
| 4.0  | SRSF8                     | serine/arginine-rich splicing factor 8                                       | †   |
| 3.8  | TRIM63                    | tripartite motif containing 63. E3 ubiquitin protein ligase                 | †   |
* | 3.8 | CXCL2                     | chemokine (C-X-C motif) ligand 2                                             | †   |
| 3.8  | PTX3                      | pentraxin 3. long                                                           | †   |
* | 3.8 | EGR1                      | early growth response 1                                                      | †   |
* | 3.5 | CXCL8                     | chemokine (C-X-C motif) ligand 8                                             | †   |
* | 3.5 | SERPIN3                   | serpin peptidase inhibitor. clade A (alpha-1 antiproteinase. antitrypsin). member 3 | †   |
| 3.5  | KCNAB2                    | potassium voltage-gated channel. shaker-related subfamily. beta member 2   | †   |
| 3.4  | CCL3L3                    | chemokine (C-C motif) ligand 3-like 3                                       | †   |
| 3.4  | HEATR9                    | HEAT repeat containing 9                                                     | †   |
* | 3.2 | TNFAIP2                   | tumor necrosis factor. alpha-induced protein 2                              | †   |
| 3.1  | TNFSF14                   | tumor necrosis factor (ligand) superfamily. member 14                       | †   |
* | 3.1 | KLF15                      | Kruppel-like factor 15                                                       | †   |
* | 3.1 | CXCL10                    | chemokine (C-X-C motif) ligand 10                                           | †   |
* | 3.1 | CSF3                      | colony stimulating factor 3 (granulocyte)                                   | †   |
... | ...                       | ...                                                                         | †   |
−3.6 | TNRC6C                    | trinucleotide repeat containing 6C                                          | †   |
−3.8 | GFR2A                     | GDNF family receptor alpha 2                                                | †   |
−4.4 | CACNA1F                   | calcium channel. voltage-dependent. L type. alpha 1F subunit                | †   |
* | −5.1 | HCAR2                     | hydroxy carbocyclic acid receptor 2                                         | †   |
−8.0 | RBBP8NL                   | RBBP8 N-terminal like                                                       | †   |

Asterisk labels genes that are also differentially expressed in DUX4c-transfected IMBs. † labels genes previously described DUX4 target genes [12].
### Table 2: Genes differentially expressed in hIMB cells 24 h after DUX4-plasmid transfection

<table>
<thead>
<tr>
<th>FC</th>
<th>Gene</th>
<th>Description</th>
<th>ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>501.4</td>
<td>RFPL2</td>
<td>ret finger protein-like 2</td>
<td>†</td>
</tr>
<tr>
<td>200.5</td>
<td>ZSCAN4</td>
<td>zinc finger and SCAN domain containing 4</td>
<td>†</td>
</tr>
<tr>
<td>184.3</td>
<td>TRIM64</td>
<td>tripartite motif containing 64</td>
<td>†</td>
</tr>
<tr>
<td>166.0</td>
<td>USP29</td>
<td>ubiquitin specific peptidase 29</td>
<td>†</td>
</tr>
<tr>
<td>140.0</td>
<td>TRIM43</td>
<td>tripartite motif containing 43</td>
<td>†</td>
</tr>
<tr>
<td>121.1</td>
<td>RFPL3</td>
<td>ret finger protein-like 3</td>
<td>†</td>
</tr>
<tr>
<td>109.1</td>
<td>PRAMEF2</td>
<td>PRAME family member 2</td>
<td>†</td>
</tr>
<tr>
<td>69.3</td>
<td>ZIM3</td>
<td>zinc finger, imprinted 3</td>
<td>†</td>
</tr>
<tr>
<td>63.9</td>
<td>TRIM49</td>
<td>tripartite motif containing 49</td>
<td>†</td>
</tr>
<tr>
<td>60.2</td>
<td>RFPL1</td>
<td>ret finger protein-like 1</td>
<td>†</td>
</tr>
<tr>
<td>56.1</td>
<td>PRAMEF1</td>
<td>PRAME family member 1</td>
<td>†</td>
</tr>
<tr>
<td>42.3</td>
<td>SLC34A2</td>
<td>solute carrier family 34 (type II sodium/phosphate cotransporter). member 2</td>
<td>†</td>
</tr>
<tr>
<td>38.4</td>
<td>LEUTX</td>
<td>leucine twenty homeobox</td>
<td>†</td>
</tr>
<tr>
<td>38.0</td>
<td>MRAP2</td>
<td>melanocortin 2 receptor accessory protein 2</td>
<td>†</td>
</tr>
<tr>
<td>36.3</td>
<td>RFPL4B</td>
<td>ret finger protein-like 4B</td>
<td>†</td>
</tr>
<tr>
<td>* 32.8</td>
<td>HPX-2</td>
<td>homeobox HPX-2</td>
<td>†</td>
</tr>
<tr>
<td>26.2</td>
<td>MBD3L2</td>
<td>methyl-CpG binding domain protein 3-like 2</td>
<td>†</td>
</tr>
<tr>
<td>24.4</td>
<td>PRAMEF9;PRAMEF25;PRAMEF19;PRAMEF22</td>
<td>PRAME family member 9;PRAME family member 25;PRAME family member 19;PRAME family member 22</td>
<td>†</td>
</tr>
<tr>
<td>19.8</td>
<td>TRIM48</td>
<td>tripartite motif containing 48</td>
<td>†</td>
</tr>
<tr>
<td>19.7</td>
<td>KHDC1</td>
<td>KH homology domain containing 1</td>
<td>†</td>
</tr>
<tr>
<td>18.0</td>
<td>PRAMEF8</td>
<td>PRAME family member 8</td>
<td>†</td>
</tr>
<tr>
<td>17.2</td>
<td>CCDC30</td>
<td>coiled-coil domain containing 30</td>
<td>†</td>
</tr>
<tr>
<td>13.6</td>
<td>DKK2</td>
<td>dickkopf WNT signaling pathway inhibitor 2</td>
<td>†</td>
</tr>
<tr>
<td>13.3</td>
<td>CLDN14</td>
<td>claudin 14</td>
<td>†</td>
</tr>
<tr>
<td>13.1</td>
<td>TRIM51;TRIM51HP</td>
<td>tripartite motif-containing 51; tripartite motif-containing 51H. pseudogene</td>
<td>†</td>
</tr>
<tr>
<td>11.8</td>
<td>FAM90A1</td>
<td>family with sequence similarity 90. member A1</td>
<td>†</td>
</tr>
<tr>
<td>10.9</td>
<td>DUX3</td>
<td>double homeobox 3</td>
<td>†</td>
</tr>
<tr>
<td>10.24</td>
<td>FRG2</td>
<td>FSHD region gene 2</td>
<td>†</td>
</tr>
<tr>
<td>8.61</td>
<td>CCNA1</td>
<td>cyclin A1</td>
<td>†</td>
</tr>
<tr>
<td>8.14</td>
<td>PNP</td>
<td>purine nucleoside phosphorylase</td>
<td>†</td>
</tr>
<tr>
<td>7.75</td>
<td>SNAI1</td>
<td>snail family zinc finger 1</td>
<td>†</td>
</tr>
<tr>
<td>7.34</td>
<td>HIST1H3H</td>
<td>histone cluster 1. H3h</td>
<td>†</td>
</tr>
<tr>
<td>6.19</td>
<td>NT5C1B</td>
<td>5'-nucleotidase. cytosolic IB</td>
<td>†</td>
</tr>
<tr>
<td>6.17</td>
<td>SRSF8</td>
<td>serine/arginine-rich splicing factor 8</td>
<td>†</td>
</tr>
<tr>
<td>5.69</td>
<td>DHR52</td>
<td>dehydrogenase/reductase (SDR family) member 2</td>
<td>†</td>
</tr>
<tr>
<td>5.33</td>
<td>RBBP6</td>
<td>retinoblastoma binding protein 6</td>
<td>†</td>
</tr>
<tr>
<td>4.96</td>
<td>MYB</td>
<td>v-myb avian myeloblastosis viral oncogene homolog</td>
<td>†</td>
</tr>
<tr>
<td>4.92</td>
<td>SNX22</td>
<td>sorting nexin 22</td>
<td>†</td>
</tr>
<tr>
<td>4.79</td>
<td>FOXP2</td>
<td>forkhead box P2</td>
<td>†</td>
</tr>
<tr>
<td>4.78</td>
<td>DGKE</td>
<td>diacylglycerol kinase. epsilon 64kDa</td>
<td>†</td>
</tr>
<tr>
<td>4.37</td>
<td>CHML</td>
<td>choroideremia-like (Rab escort protein 2)</td>
<td>†</td>
</tr>
<tr>
<td>4.32</td>
<td>HBEGF</td>
<td>heparin-binding EGF-like growth factor</td>
<td>†</td>
</tr>
<tr>
<td>4.14</td>
<td>KCNA2B</td>
<td>potassium voltage-gated channel. shaker-related subfamily. beta member 2</td>
<td>†</td>
</tr>
<tr>
<td>4.10</td>
<td>SPINK1</td>
<td>serine peptidase inhibitor. Kazal type 1</td>
<td>†</td>
</tr>
<tr>
<td>3.84</td>
<td>PLA2G5</td>
<td>phospholipase A2. group V</td>
<td>†</td>
</tr>
<tr>
<td>3.30</td>
<td>FLRT3</td>
<td>fibronectin leucine rich transmembrane protein 3</td>
<td>†</td>
</tr>
<tr>
<td>3.22</td>
<td>HIST1H3F</td>
<td>histone cluster 1. H3f</td>
<td>†</td>
</tr>
<tr>
<td>3.20</td>
<td>ESM1</td>
<td>endothelial cell-specific molecule 1</td>
<td>†</td>
</tr>
<tr>
<td>3.17</td>
<td>GRAMD1C</td>
<td>GRAM domain containing 1C</td>
<td>†</td>
</tr>
<tr>
<td>3.01</td>
<td>SIAH1</td>
<td>siah E3 ubiquitin protein ligase 1</td>
<td>†</td>
</tr>
<tr>
<td>...</td>
<td>...</td>
<td>...</td>
<td>†</td>
</tr>
<tr>
<td>−3.19</td>
<td>JAKMIP3</td>
<td>Janus kinase and microtubule interacting protein 3</td>
<td>†</td>
</tr>
<tr>
<td>* −3.36</td>
<td>HCAR2</td>
<td>hydroxycarboxylic acid receptor 2</td>
<td>†</td>
</tr>
<tr>
<td>−3.51</td>
<td>LMO7DN</td>
<td>LMO7 downstream neighbor</td>
<td>†</td>
</tr>
<tr>
<td>−4.10</td>
<td>RBBP8NL</td>
<td>RBBP8 N-terminal like</td>
<td>†</td>
</tr>
<tr>
<td>−7.00</td>
<td>GFRA2</td>
<td>GDNF family receptor alpha 2</td>
<td>†</td>
</tr>
<tr>
<td>−8.72</td>
<td>CACNA1F</td>
<td>calcium channel. voltage-dependent. L type. alpha 1F subunit</td>
<td>†</td>
</tr>
</tbody>
</table>

Asterisk labels genes that are also differentially expressed in DUX4c-transfected IMBs.
Table 3: Genes differentially expressed in hIMB cells 12 h after DUX4c-plasmid transfection

<table>
<thead>
<tr>
<th>FC</th>
<th>Gene</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>19.1</td>
<td>HPX-2</td>
<td>homeobox HPX-2</td>
</tr>
<tr>
<td>13.2</td>
<td>DUX3</td>
<td>double homeobox 3</td>
</tr>
<tr>
<td>4.1</td>
<td>SERPIN3A</td>
<td>serpin peptidase inhibitor. clade A (alpha-1 antiproteinase. antitrypsin). member 3</td>
</tr>
<tr>
<td>3.8</td>
<td>ABCA1</td>
<td>ATP-binding cassette. sub-family A (ABC1). member 1</td>
</tr>
<tr>
<td>3.4</td>
<td>CCL20</td>
<td>chemokine (C-C motif) ligand 20</td>
</tr>
<tr>
<td>3.0</td>
<td>GCG</td>
<td>glucagon</td>
</tr>
<tr>
<td>3.0</td>
<td>CXCL3</td>
<td>chemokine (C-X-C motif) ligand 3</td>
</tr>
<tr>
<td>2.7</td>
<td>CXCL2</td>
<td>chemokine (C-X-C motif) ligand 2</td>
</tr>
<tr>
<td>2.7</td>
<td>TNFAIP2</td>
<td>tumor necrosis factor. alpha-induced protein 2</td>
</tr>
<tr>
<td>2.7</td>
<td>APOC1</td>
<td>apolipoprotein C-I</td>
</tr>
<tr>
<td>2.6</td>
<td>APOE</td>
<td>apolipoprotein E</td>
</tr>
<tr>
<td>2.6</td>
<td>MFSD2A</td>
<td>major facilitator superfAMILY domain containing 2A</td>
</tr>
<tr>
<td>2.5</td>
<td>CLSTN2</td>
<td>calsyntenin 2</td>
</tr>
<tr>
<td>2.5</td>
<td>HEATR9</td>
<td>HEAT repeat containing 9</td>
</tr>
<tr>
<td>2.5</td>
<td>EFN1</td>
<td>ephrin-A1</td>
</tr>
<tr>
<td>2.5</td>
<td>CCL2</td>
<td>chemokine (C-C motif) ligand 2</td>
</tr>
<tr>
<td>2.5</td>
<td>CXCL1</td>
<td>chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity. alpha)</td>
</tr>
<tr>
<td>2.5</td>
<td>TNFAIP6</td>
<td>tumor necrosis factor. alpha-induced protein 6</td>
</tr>
<tr>
<td>2.5</td>
<td>NFIJ1</td>
<td>nuclear factor. interleukin 3 regulated</td>
</tr>
<tr>
<td>2.5</td>
<td>PTX3</td>
<td>pentraxin 3, long</td>
</tr>
<tr>
<td>2.4</td>
<td>FOXO1</td>
<td>forkhead box O1</td>
</tr>
<tr>
<td>2.4</td>
<td>KLF15</td>
<td>Kruppel-like factor 1</td>
</tr>
<tr>
<td>2.4</td>
<td>FOS</td>
<td>FBJ murine osteosarcoma viral oncogene homolog</td>
</tr>
<tr>
<td>2.3</td>
<td>NR4A3</td>
<td>nuclear receptor subfamily 4. group A. member 3</td>
</tr>
<tr>
<td>2.3</td>
<td>CHI3L2</td>
<td>chitinase 3- like 2</td>
</tr>
<tr>
<td>2.3</td>
<td>MTSS1</td>
<td>metastasis suppressor 1</td>
</tr>
<tr>
<td>2.3</td>
<td>DEFB119</td>
<td>defensin. beta 119</td>
</tr>
<tr>
<td>2.3</td>
<td>CFHR4</td>
<td>complement factor H-related 4</td>
</tr>
<tr>
<td>2.3</td>
<td>PTGDS</td>
<td>prostaglandin D2 synthase 21kDa (brain)</td>
</tr>
<tr>
<td>2.2</td>
<td>CSF3</td>
<td>colony stimulating factor 3 (granulocyte)</td>
</tr>
<tr>
<td>2.2</td>
<td>CYTIP</td>
<td>cytohesin 1 interacting protein</td>
</tr>
<tr>
<td>2.2</td>
<td>BCL7A</td>
<td>B-cell CLL/Lymphoma 7A</td>
</tr>
<tr>
<td>2.2</td>
<td>CFI</td>
<td>complement factor 1</td>
</tr>
<tr>
<td>2.2</td>
<td>CYP21A2</td>
<td>cytochrome P450. family 21. subfamily A. polypeptide 2</td>
</tr>
<tr>
<td>2.2</td>
<td>ZC3H12A</td>
<td>zinc finger CCCH-type containing 12A</td>
</tr>
<tr>
<td>2.1</td>
<td>CXCL8</td>
<td>chemokine (C-X-C motif) ligand 8</td>
</tr>
<tr>
<td>2.1</td>
<td>PDE4DIP</td>
<td>phosphodiesterase 4D interacting protein</td>
</tr>
<tr>
<td>2.1</td>
<td>CFB</td>
<td>complement factor B</td>
</tr>
<tr>
<td>2.1</td>
<td>HGF</td>
<td>hepatocyte growth factor (hepatopoietin A; scatter factor)</td>
</tr>
<tr>
<td>2.1</td>
<td>WISP1</td>
<td>WNT1 inducible signaling pathway protein 1</td>
</tr>
<tr>
<td>2.1</td>
<td>EGR1</td>
<td>early growth response 1</td>
</tr>
<tr>
<td>2.1</td>
<td>YAP1</td>
<td>Yes-associated protein 1</td>
</tr>
<tr>
<td>2.1</td>
<td>AOCC</td>
<td>amine oxidase. copper containing 3</td>
</tr>
<tr>
<td>2.1</td>
<td>TNFAIP3</td>
<td>tumor necrosis factor. alpha-induced protein 3</td>
</tr>
<tr>
<td>2.1</td>
<td>ENDOV</td>
<td>endonuclease V</td>
</tr>
<tr>
<td>2.0</td>
<td>PIM3</td>
<td>Pim-3 proto-oncogene. serine/threonine kinase</td>
</tr>
<tr>
<td>2.0</td>
<td>NFKBIE</td>
<td>nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor. epsilon</td>
</tr>
<tr>
<td>2.0</td>
<td>IPCEF1; CNKSR3</td>
<td>interaction protein for cytohesin exchange factors 1; CNKSR family member 3</td>
</tr>
<tr>
<td>2.0</td>
<td>LSMEM1</td>
<td>leucine-rich single-pass membrane protein 1</td>
</tr>
<tr>
<td>2.0</td>
<td>TMEM165</td>
<td>transmembrane protein 165</td>
</tr>
<tr>
<td>2.0</td>
<td>COLEC12</td>
<td>collectin sub-family member 12</td>
</tr>
<tr>
<td>-2.1</td>
<td>HIP1</td>
<td>huntingtin interacting protein 1</td>
</tr>
<tr>
<td>-2.1</td>
<td>SAPCD2</td>
<td>suppressor APC domain containing 2</td>
</tr>
<tr>
<td>-2.1</td>
<td>CDCA7</td>
<td>cell division cycle associated 7</td>
</tr>
<tr>
<td>-2.2</td>
<td>PRPH2</td>
<td>peripherin 2 (retinal degeneration. slow)</td>
</tr>
<tr>
<td>-2.2</td>
<td>AGMAT</td>
<td>agmatine ureohydrolase (agmatinase)</td>
</tr>
<tr>
<td>-2.2</td>
<td>KRTAP1-5</td>
<td>keratin associated protein 1-5</td>
</tr>
<tr>
<td>-2.3</td>
<td>HMGA2</td>
<td>high mobility group AT-hook 2</td>
</tr>
<tr>
<td>-2.3</td>
<td>PAQR5</td>
<td>progestin and adipoQ receptor family member V</td>
</tr>
<tr>
<td>-2.3</td>
<td>MCM4</td>
<td>minichromosome maintenance complex component 4</td>
</tr>
<tr>
<td>-2.4</td>
<td>CDC6</td>
<td>cell division cycle 6</td>
</tr>
<tr>
<td>-2.6</td>
<td>SSTR1</td>
<td>somatostatin receptor 1</td>
</tr>
</tbody>
</table>

Asterisk labels genes that are also differentially expressed in DUX4-transfected IMBs.
Several functional categories including, transcription, angiogenesis, neuron development, cell signaling, cellular transport, protein degradation, and protein complex assembly that have not reach statistical significance in our study, were attributed to DUX4 target genes previously [14, 12, 47]. The validity of some of these functional categories has been experimentally proven: DUX4 overexpression in human myoblasts has been shown to induce genes involved in protein degradation [16] and interfere with protein ubiquitination.
DUX4 overexpression in mouse embryonic stem cells (ES) has been shown to induce neuroectoderm program [49]; the involvement of DUX4 in transcription regulation has also been addressed [14]. Finally, DUX4 target genes found in this study also include FRG2 and KLF15 - genes shown previously to be overexpressed in FSHD; this is in agreement with an observation that DUX4 target genes are differentially expressed in FSHD [50].

As compared to DUX4c, DUX4 overexpression resulted in a differential expression of more genes involved in chemotaxis, ion transport, and protein degradation. Conversely, all differentially expressed genes related to protein complex assembly were exclusively controlled by DUX4c (Figure 2).

**DUX4 overexpression results in upregulation of CXCR4 and SDF1 gene expression in various cell types**

DUX4 and DUX4c transcriptome signatures contained genes encoding chemokines. Of 18 chemokine genes reliably detected by the microarray (intensity > 50) in MB, 10 and 7 were at least 1.5-fold upregulated in DUX4- and DUX4c-overexpressing MB, respectively (Figure 3A, 3B). A relatively weakly expressed CXCR4 chemokine receptor gene was upregulated 2 to 5-fold in DUX4- but not DUX4c-overexpressing MB as compared to the controls. Other chemokine receptor genes were either undetectable or not differentially expressed. qPCR and immunofluorescence microscopy analysis of CXCR4 expression in MB and mesenchymal stromal cells isolated from human bone marrow cells (BMSC) transfected with the DUX4 plasmid confirmed the results of transcriptome profiling (Figures 4, 5 and Supplementary Figure S3). Furthermore, we observed a significant upregulation of CXCR4 expression in several other cell types transfected with DUX4 including human keratinocyte cell line HaCat, dermal fibroblasts Dfb and mesenchymal stromal cells isolated from adipose tissue (ADAS) (data not shown).

CXCR4 receptor is activated by the interaction with its only known ligand SDF1. Our microarray analysis did not detect a differential expression of SDF1 gene (Figure 3C, 3D); however, we observed a moderate but statistically significant upregulation of SDF1 mRNA and protein in DUX4- but not DUX4c-overexpressing MB (Figure 4A, 4B). DUX4-transfected myoblasts also secreted more SDF1 protein into extracellular medium (Figure 4D). SDF1 is also known to bind to a scavenger receptor CXCR7, however, no change in CXCR7 expression level was observed upon DUX4 or DUX4c overexpression (Figure 3C, 3D). It is also unlikely that DUX4 expression is essential for CXCR4 or SDF1 expression as these genes are known to be expressed in various cell types, and DUX4 expression is confined to embryonic and germinal cells [17, 11].

**DUX4 overexpression stimulates migration of mesenchymal stem cells**

The efficiency of CXCR4 signaling depends on the expression level of both SDF1 and CXCR4 genes (reviewed in [41]). Our results thus suggested that DUX4 might regulate cell mobility and migration. To test the migration and chemoattractive properties of cells overexpressing DUX4 and DUX4c, we used a Transwell assay. Migrating BMSC were plated on an upper layer of a permeable membrane placed in a Transwell insert and chemoattractant-producing human myoblasts were plated to the lower chamber section of the Transwell system (Figure 6H). To test the effect of DUX4- and DUX4c overexpression on chemoattractive properties of MB, we transfected them with DUX4 and DUX4c plasmids and counted the number of untransfected stromal cells derived from human bone marrow cells (BMSC) that crossed the membrane (Figure 6A). We observed a more efficient migration of BMSC towards DUX4- but not DUX4c overexpressing MB. The effect was completely blocked if antibodies against SDF1 were added to the culture medium (Figure 6F). We have also tested whether DUX4 overexpression could increase chemoattractive properties of other cell types. We overexpressed DUX4 in TE671 rhabdomyosarcoma cell line, known to be resistant to high levels of DUX4 expression [13, 51], human immortalized myoblasts (MB) and immortalized keratinocyte cells line HaCat and found that DUX4 overexpression also increases the chemoattractivity of these cells to BMSC (data not shown).

Next, we tested whether DUX4 or DUX4c overexpression could modify migration properties of BMSC, and observed an increase of migration rate of DUX4- but not DUX4c-transfected BMSC towards untransfected MB (Figure 6B). This effect was further increased if DUX4 but not DUX4c was simultaneously overexpressed in both BMSC and MB (Figure 6C, 6D). Adding CXCR4 antibodies to the culture medium completely abolished the effect of DUX4 overexpression on cell migration (Figure 6G). Cell migration experiments have been carried out 24 h after the transfection as apoptosis and necrosis rate of the transfected cells at this time point was not significantly different from non-transfected controls (Supplementary Figure S1) arguing against the possibility that cytotoxic effect of DUX4 overexpression could introduce a bias in our assay.

To rule out the possibility that DUX4 overexpression could affect BMSC and ADAS multipotency, we then induced adipogenic differentiation of DUX4-transfected BMSC. We found the number of resulting adipocytes unchanged as compared to a control plasmid-transfected BMSCs, thus arguing against the possibility that DUX4 altered adipogenic differentiation potential of BMSC and ADAS (Supplementary Figure S2).

We conclude that DUX4 but not DUX4c overexpression increases chemoattractivity of several cell
Figure 3: Chemokine (A, B) or chemokine receptor (C, D) gene mRNA expression (microarray) in human immortalized myoblasts (MB) 12 h or 24 h after transfection with DUX4 (A, C) or DUX4c (B, D) plasmids. Gene names are divided in 3 classes: highly expressed (int > 50), low expression (3 < int < 50) and non-detectable (in < 3) sorted according to fold change.
types for MSC migration and also increased migration rate of BMSC when overexpressed in them. The difference in transcriptome signatures of DUX4 and DUX4c-overexpressing myoblasts is thus clearly translated into different biological roles of these transcription factors.

**DISCUSSION**

**DUX4 and SDF1-CXCR4 axis in the normal organism**

DUX4 is a powerful transcriptional regulator with an unknown physiological role in normal cells. In vitro, full-length DUX4 is expressed in human embryonic and mesenchymal stem cells [17] and induced pluripotent stem cells [11]; its expression is downregulated in the process of differentiation of these cells. DUX4 expression cannot be detected in fully-differentiated cells such as primary myoblasts or fibroblasts where only DUX4-s, a shorter non-toxic form of DUX4 resulting from an alternative splicing of DUX4 gene could be detected.

In normal adult human tissues, full-length DUX4 is expressed only in testis; in somatic tissues including skeletal muscles, liver and heart only DUX4-s transcript was detectable [11]. The pattern of full-length DUX4 expression is indicative of a role at early stages of human development. However, besides the observation that DUX4 overexpression induced neuroectodermal program in murine embryonic stem cells, developmental functions of DUX4 remain unknown. Linking DUX4 with cellular migration described here may thus contribute to the understanding of a physiological role of DUX4 in development.

In the course of vertebrate development, SDF1 and CXCR4 are essential for colonization of the bone marrow by hematopoietic stem and progenitor cells (HSPCs) (reviewed in [52, 53, 39, 38]), colonization of gonads by primordial germ cells (PGCs) [54] (reviewed in [38]); neurogenesis (reviewed in [38, 55]); cardiogenesis and vascular formation [56]; limb myogenesis [57–61]. It is tempting to speculate that as an activator of CXCR4 and SDF1 expression, DUX4 might be also involved in these processes.

The role of DUX4 in development could, in principle, be addressed using loss of function mouse models. Mouse genome contains DUX4 homologs Duxbl...
(also named *Duxl*) [62, 63] and *Dux*. The degree of amino acid identity of Duxbl and DUX4 reaches 65% in the most conserved region (second homeobox DNA binding domain) [62]. Expression pattern of Duxbl (ovary, eyes, testes and brain of adult mice and developing muscles of mouse embryos [64]) demonstrates a certain similarity to the DUX4 expression pattern. Functional analysis of Duxbl demonstrated that *Duxbl* overexpression increased myoblast proliferation but repressed their myogenic differentiation [65] which to certain extent recapitulated the effect of *DUX4* overexpression on myogenic differentiation.

Another mouse homolog, Dux is only 60% identical to DUX4 in its most conserved region; its expression pattern is also less similar to that of DUX4. Dux expression was demonstrated in adult mouse brain, heart, liver and lungs and was almost undetectable in skeletal muscle [62]; functional analysis of this gene was not conducted. Duxbl or Dux loss-of-function mouse models are not yet available, and their relevance for understanding the physiological role is not clear.

### DUX4 and SDF1-CXCR4 axis in pathology

While in normal adult organism the role of DUX4 is unknown and might be limited to germline, the role of DUX4 in pathology (i.e. in Facioscapulohumeral dystrophy or FSHD) has been extensively explored. In this disease, DUX4 expression could be detected in muscle cells and tissues [11] and is thought to contribute to the pathological phenotype by inducing apoptosis, provoking the sensitivity to oxidative stress and inhibiting myogenic differentiation. Inhibition of myogenic differentiation is one of the best understood functions of DUX4 in FSHD. Murine muscle satellite cells expressing human DUX4 are unable to properly differentiate *in vitro* [21] or regenerate skeletal muscle tissue *in vivo* [66].

**Figure 5: DUX4-transfected cells overexpress SDF1 and CXCR4.** Immunofluorescence analysis of CXCR4 and DUX4 expression in human immortalized myoblasts (MB) (A) and bone marrow-derived mesenchymal stromal cells (BMSCs) (B) 24 h after the transfection with pCI-NeoDUX4 plasmid. Formaldehyde-fixed cells were stained with CXCR4, SDF1 and DUX4 antibodies, representative images are shown; scale bar 50 μm.
Inhibition of the myogenic program by DUX4 could be explained by a similarity of recognition sites of DUX4 and Pax3/7 transcription factors essential for the commitment of myogenic progenitors resulting in an interference with the early myogenic differentiation steps [14]. It has also been demonstrated that DUX4 induced the expression of muscular atrophy-related genes [67, 16] myogenic microRNAs [68] and transcription factors [14, 47] suggesting that DUX4 might also interfere with later stages of myogenic differentiation.

Interestingly, CXCR4 is also involved in the regulation of myogenic differentiation. CXCR4 is expressed on the surface of both proliferating and differentiated C2C12 cells [58, 61, 69]. SDF1 expression is increased while CXCR4 decreased during myogenic differentiation of rat myoblasts [70]; however, the role of CXCR4-SDF1 axis in myogenic differentiation remains controversial. Some reports have shown inhibition of myogenic differentiation by SDF1 of CXCR4 signaling [69] or no effect [70]. Other reports have shown that SDF1 induced myotube formation while CXCR4 inhibition via siRNA blocked C2C12 differentiation [71]. The mechanism of CXCR4-dependent regulation of myogenic differentiation is thought to involve MAPK signaling. Intriguingly, MAPK signaling-related genes were identified in DUX4 transcriptomic signature [47]. CXCR4 as one of DUX4 target genes might thus also contribute to FSHD etiology.

Besides an abnormal myogenic differentiation, an accumulation of leukocytes has been also documented in FSHD muscles [72]; the mechanism of this phenomenon is currently unknown. It has been demonstrated that CXCR4 receptor plays a key role in chronic inflammatory conditions such as inflammatory bowel disease (reviewed in [73]), chronic allergic lung inflammation, idiopathic pulmonary fibrosis, liver fibrosis [74], rheumatoid arthritis (reviewed in [75]).

Our results allow us to put forward a hypothesis that DUX4 overexpression resulting in SDF1 expression in FSHD muscles might result in an increased migration of leukocytes to FSHD muscles. It is plausible therefore that DUX4 might be involved in these processes as its aberrant expression in FSHD muscles might activate SDF1 and thus attract circulating CXCR4+ leukocytes which would result in their infiltration to FSHD muscles. Again, this possibility could, in principle, be tested using mouse models of ectopic expression of human DUX4 that have recently been described. Mice expressing human DUX4 under the control of its natural promoter did not show visible phenotypic anomalies except for the eye keratitis of unknown etiology [21]. At the same time, mice expressing DUX4 under the control of a leaky doxycycline-inducible promoter in retina, testis, skin, brain, kidney, and lung, had scaly skin, muscle weakening, increased retina neovascularization, males demonstrated a defect in gametogenesis [66]. Although the latter mouse

Figure 6: DUX4 and DUX4c expression increases migration rate of human bone marrow stem cells (BMSC) towards human immortalized myoblasts (MB) in a transwell assay. BMSC and MB cells were plated to the upper- and the lower wells of a Transwell chamber respectively and the number of BMSC that crossed the membrane and adhered to its lower surface was quantified. (A) Migration of non-transfected BMSCs towards MB transfected with DUX4-, DUX4c-plasmid or an empty-vector control (e.v.); (B) Migration of BMSCs transfected with DUX4-, DUX4c-plasmid or e.v. towards non-transfected MB; (C) Migration of BMSCs transfected with DUX4- or e.v. towards DUX4- or e.v.-transfected MB; (D) Migration of BMSCs transfected with DUX4c- or e.v. towards DUX4c- or e.v.-transfected MB; (E) Migration of BMSCs transfected with DUX4-, DUX4c- or e.v. towards DUX4- or e.v.-transfected MB; (F) Effect of SDF1 antibody on BMSC migration towards MB transfected with DUX4- or DUX4c-plasmid or e.v. (G) Effect of CXCR4 antibody on migration of BMSC transfected with DUX4-plasmid or e.v. towards DUX4-plasmid or e.v.-transfected MB; (H) Schematic representation of DUX4 overexpression impact on BMSC cell migration towards MB. (*), p-value < 0.05 as compared to control; #, non-significant; migration to e.v.-transfected cells was set to 100%, error bars correspond to SD.
model had some phenotypical features common to FSHD, its relevance as a model of FSHD is thus unclear.

**DUX4 in cancer**

Finally, DUX4 is also known to be expressed in many cancer cell lines including rhabdomyosarcoma RD (CCL-136) and RMS13 (CRL-2061) [13, 76], cervix carcinoma HeLa, lung adenocarcinoma A549 cell lines [76] and in non-small cell lung cancer (NSCLC) cells [76]; DUX4 or a homologous transcript was detected in cervical carcinoma cell line C33A [77]. Recurrent DUX4 fusions have been detected in B cell acute lymphoblastic anemia [78], embryonal rhabdomyosarcoma [79], Ewing-like sarcomas [80] and pediatric primitive round cell sarcomas [81]. The mechanism of DUX4 upregulation in cancer cells remains unknown, although it has been proposed that it is linked to demethylation of the 3.3 kb repeats harboring DUX4 ORF [82, 77, 83].

Tumor cells are known to secrete SDF, inflammatory cytokines and growth factors which together promote MSC homing to the tumor site [84]. MSC infiltration has been proven beneficial for some tumor types [85]. One possibility that is suggested by our results but has not been tested in this study is that DUX4 might contribute to the MSC infiltration into tumors. Another possibility that was not addressed in the present study is that DUX4 expression might influence metastatic potential of cancer cells via CXCR4-SDF1 axis. SDF1-CXCR4 signaling is also involved in migration of cancer cells to the sites of metastasis (SDF1-expressing tissues, such as bone marrow and lung) including breast, lung, ovarian, thyroid, rhabdomyosarcoma and others (over 20 human tumor types (reviewed in [86]) [53, 87, 86–89]. Our study thus prompts to test whether DUX4 overexpressing tumors demonstrate an increased metastatic potential as compared to DUX4-negative tumors.

**MATERIALS AND METHODS**

**Cell culture conditions, plasmids and transfection**

Human immortalized myoblasts (MB) generated from a healthy subject (a kind gift of Dr. V. Mouly, Institute of Myology, Paris) were cultured in the media composed of 4 parts of high-glucose DMEM, 1 part of Medium 199 (Sigma #M4530) and supplemented with 20% FBS 4 mM L-glutamine 50 µg/ml gentamicin, 1 µg/ml Amphotericin B, 2.5 ng/ml human recombinant HGF (Sigma #H1404) and 1 mM dexamethasone (Sigma #D4902) as described previously [90].

Human primary myoblasts were isolated from skeletal muscle biopsies of healthy subjects and purified using CD56/NCAM magnetic beads (Miltenyi Biotec) as previously described [91], preserved in liquid nitrogen and transported for future use. After unfreezing, the myoblasts were cultured in proliferation medium (high-glucose DMEM (here and below #D6546, Sigma), 20% FBS FBS (Millerrium #BWSTSH1810/500), 4 mM L-glutamine (Sigma #68540–25 G), 50 µg/ml gentamicin (G1397 Sigma), 1 µg/ml Amphotericin B (Fungizone, Gibco #15290–018)), passaged at a cell confluence not exceeding 30 % and used for transfection and tests up to passage 5 or earlier to avoid cellular senescence and spontaneous differentiation.

Both primary and immortalized myoblasts were cultured in cell culture dishes coated with sterile 0.1% solution of collagen powder (#C7661 Sigma) in 0.2% acetic acid.

Human bone marrow-derived mesenchymal cells (BMSC) were isolated as previously described [92]. Briefly, mononuclear cells were isolated from bone marrow aspirates from healthy donors using centrifugation in Histopaque-1077 density gradient (Sigma) at 400 g for 30 min at room temperature; the resulting cells were washed 3 times with DMEM, plated at 10^6 cells/cm2 in cell culture flasks (Greiner Bio-One) and cultured the growth medium (low-glucose DMEM (Gibco) supplemented with 10% fetal bovine serum (FBS) (HyClone), 2 mM GlutaMAX™ (Gibco), and 50 U/ml of penicillin and 50 µg/ml of streptomycin (Gibco); medium was changed every 3 days.

Human adult adipose tissue-derived stem cells (ADAS) were isolated as previously described [92]. Briefly, the adipose tissue aspirates was washed with phosphate-buffered saline (PBS), containing 50 U/ml of penicillin and 50 µg/ml of streptomycin (Gibco), then digested at 37°C for 60 min with 0.075% collagenase type I (Worthington). The cell suspension was washed with DMEM, containing 10% FBS and centrifuged at 300 g for 10 min. The pellet was resuspended in 160 mM NH4Cl and incubated at room temperature for 10 min to lyse contaminating red blood cells. The cell suspension was centrifuged as detailed above, the pellet was resuspended in DMEM supplemented with 20% FCS filtered through a 100-um nylon mesh to remove cellular debris, plated at culture flasks and incubated overnight at 37°C, 5% CO2. Following incubation, the flasks were washed extensively with PBS to remove residual nonadherent blood cells. ADAS were cultured in growth medium DMEM/F12 (Gibco), supplemented with 10% FBS, 2 mM GlutaMAX™, 50 U/ml of penicillin and 50 µg/ml of streptomycin (Gibco). The medium was changed every 3 days, cells were maintained at subconfluent levels.

TE-671 and HaCaT cell lines were cultured in DMEM medium supplemented with 4.5 g/L glucose (Gibco), 2 mM L-glutamine, 10% fetal bovine serum and 100 µ/ml penicillin and 100 µg/ml of streptomycin.

**Adipogenic differentiation**

ADAS and BMSC were plated in 12-well plates at a density of 5 × 10^3 cells cm^-2 and transfected with
DUX4-, DUX4c- or control vector when indicated. After 24 h the growth media was replaced with adipogenic induction medium: DMEM, 10% FBS, 0.5 mM isobutylmethylxantine (Sigma), 1 uM dexamethasone (Sigma), 10 uM insulin (Sigma), 0.2 mM indomethacin (Sigma); the medium was changed every three days. After 21 days cells were fixed with 4% paraformaldehyde in PBS and lipid droplets were revealed by histochemical staining with Oil Red O dye (Sigma) for neutral fats. For quantification, Oil Red O stain was extracted with 100% isopropanol for 5 min, absorbance was measured at 492 nm and normalized to the number of cells; 100% isopropanol was used as a background control; the experiments were performed in quadruplicates.

Transfection. 8 × 10⁴ of human MB cells were resuspended in 400 ml of corresponding culturing medium, mixed with 80 ml of OptiMEM (Gibco #31985062) containing 240 ng of plasmid DNA and 0.24 ml Lipofectamine 2000 (Invitrogen, #11668–019) and plated into 1 well of a 12-well plate (2.1 × 10⁵ cells/cm²); medium was changed 6 h after the transfection. The transfection efficiency was around 40%. 2 × 10⁵ BMSC or ADAS cells were plated in a well of a 12-well plate (5 × 10⁵ cells/cm²) and transected using 1 μg of plasmid DNA and 1 ml of Lipofectamine 2000™ (Invitrogen) according to the supplier’s instructions; medium was changed 6 h after the transfection. The transfection efficiency was 80–90%.

To overexpress DUX4 and DUX4c, we used pCI-Neo-DUX4 [3] and pCI-Neo-DUX4c [22] plasmids containing human DUX4 and DUX4c ORFs genes under control of the CMV promoter (a kind gift of Alexandra Belayew and Frederique Coppée, University of Mons, Belgium); Following control plasmids were used: pCI-Neo (Promega), phrGFP (Stratagene) and pCI-Neo-DUX1 [2].

**Immunofluorescence staining**

24 h after the transfection MB or BMSC cells were fixed with 2% PFA (Euromedex) in PBS for 5 min, permeabilized with 0.5% triton X-100 (Sigma-Aldrich) in PBS for 5 min, blocked with 5% BSA (Euromedex) in PBS for 1 h, incubated with mouse monoclonal antibodies against DUX4 clone 9A12 [67] (kindly donated by Alexandra Belayew, University of Mons, Belgium) diluted 1:50; rabbit polyclonal antibody against CXCR4 (Abcam #ab 2074) diluted 1:100 or rabbit polyclonal antibody against DUX4 clone 9A12 [67] (kindly donated by Alexandra Belayew and Frederique Coppée, University of Mons, Belgium) diluted 1:50; rabbit polyclonal antibody against CXCR4 (Abcam #ab 2074) diluted 1:100 or Alexa Fluor 488 anti-mouse IgG (Life Technologies #A-21441, 1:100) for 2 h or Alexa Fluor 488 anti-mouse IgG (Life Technologies #A-21200, 1:100) for 1 h 2.5% PBS in BSA and mounted with a mounting medium containing DAPI (Vector laboratories), observed under a fluorescent microscope (Microvision instruments, excitation/emission: 488/519 nm, green fluorescence);

**Western blot**

Whole cell protein extracts were prepared from frozen immortalized or primary myoblast cell pellets using TENT buffer (150 mM NaCl, 1 mM EDTA, 50 mM Tris-HCl pH 7.5, 0.5% NP-40) [93] supplemented with anti-protease and anti-phosphatase inhibitor cocktails (#04693159001, #04906845001, Roche), separated on 8% PAAG, transferred to a nitrocellulose membrane (Amersham), blocked with 5% milk/PyTBST, hybridized with primary antibodies 9A12 [67] recognizing DUX4 and DUX4c diluted 1:2000, washed with 1 × PyTBST (10 mM Tris-HCl pH 7.4, 75 mM NaCl, 1 mM EDTA, 0.1% Tween 20) [94] to reduce background, hybridized with secondary antibodies conjugated to HRP (SantaCruz #sc2030, #sc2768, #sc2005) diluted 1.2000, revealed with ECL+ (GE Healthcare), exposed to X-ray film (Amersham) and developed in a chemical film processor (FujiFilm). Quantification of scanned X-ray images was performed using ImageJ. After exposition the membranes were stripped in a solution containing 2%SDS and 100 mM beta-mercaptoethanol buffered with 62.5 mM TrisHCl, rebloked in 5% BSA/PBS overnight and rehybridized with mouse monoclonal antibodies against actin (Millipore #mab1501) diluted 1:10 000.

Flow cytometry apoptosis assay was performed using a CF™488A Annexin V and 7-AAD Apoptosis Kit (Biotium, cat # 30060). 24 or 72 h after transfection, MB or BMSC cells were trypsinized, centrifuged, resuspended in PBS. To avoid the loss dead cells, the media with detached cells was also collected and centrifuged at 300 g for 5 min, the cells pellet was resuspended in PBS. The cells were stained according manufacture protocol. Briefly, cells were resuspended at 5 × 10⁵ cells/ml in 1X Annexin Binding Buffer, 5 ul of Annexin V and 2 ul of 7-AAD working solutions were added into the cell suspension and incubated at 4°C for 30 min in a dark. Then 400 ul of 1X Annexin Binding Buffer was added and probes were analyzed by flow cytometry on the Cell Lab Quanta SC (Beckman Coulter, Brea, CA, USA).

**Transcriptome profiling**

RNA from human MB cells 12- and 20 h after the transfection with pCI-Neo-DUX4, pCI-Neo-DUX4c or pCI-Neo plasmids was extracted using Trizol (Invitrogen) as instructed by the producer and further purified with silica column cleanup using Nucleospin RNA Extraction kit (Macherey Nagel). 500 ng of RNA were used to synthesize Cy3- (control) and Cy5- (DUX4- and DUX4c-transfected MB) labeled probes in a two-step procedure using Agilent Fluorescent Low Input Linear Amplification kit. Mix. Labeled probes were then hybridized to Gene Expression microarrays (4 × 44 k #G4112F, Agilent) and scanned using Agilent G2505C DNA Microarray scanner as instructed by the manufacturer. Scanned
images were then analysed using the Feature Extraction software (Agilent, version 10.5.1.1) and gene expression fold change was calculated using Rosetta Resolver (version 7.2.2.0). In the case of DUX4-transfected cells, genes with FC < -3 and Int1 (Cy3) > 50 were considered downregulated; genes with FC > 3 and Int2 (Cy5) > 50 were considered upregulated; in the case of DUX4c-transfected cells, genes with FC < -2 and Int1 (Cy3) > 50 were considered downregulated; genes with FC > 2 and Int2 (Cy5) > 50 were considered upregulated. Gene symbols and descriptions corresponding to significant Agilent IDs were retrieved from the Agilent microarray annotation file and db2db and DAVID gene ID conversion tools. In case of disagreement between the sources, HGNC database (http://www.genenames.org/) was consulted. Probes corresponding to non-annotated genes were not analyzed. Protein-coding genes differentially expressed in DUX4 and DUX4c transfected MB were used for functional annotation with DAVID (http://david.abcc.ncifcrf.gov/) using GOTERM_BP_FAT list and the default background. The stringency of functional annotation clustering was set to “medium”. Clusters with similar biological functions containing at least one significant GO term (acceptable significance: p-value < 0.05, FDR < 20) were manually combined using Microsoft Excel with Ablebits add-ons “Cell merge” (https://www.ablebits.com/) resulting is superclusters “Cell cycle”, “Apoptosis” etc.; The significance of a supercluster was considered to be equal to p-value and FDR corresponding to the most significant GO term within this supercluster.

RT-PCR

Total RNA was extracted using Trizol (Invitrogen) as instructed by the producer; the traces of phenol and salts were eliminated with 2 supplementary chlorophorm extractions, ethanol precipitation and two additional washes with 70% ethanol. 100 ng of purified RNA was then reverse transcribed using ReverTaid H minus Reverse transcriptase (Fermentas #EP0451) as instructed by the producer, random hexamers and other RT components were also from Fermentas. cDNA was then diluted 10 times and 2 mlk was mixed with primers (300 nM final) FastStart Universal SYBR Green Master mix (ROX) (Roche #0491385001) in a final volume of 20 mlk and analyzed on Step One plus instrument (Applied Biosystems). The sequence of primers (Invitrogen) used: SDF1-F2 5'-GAACGCCAAGGTGGTGTCGTG; SDF1-R2 5'-TCTGTAGCTCAGGCTGACGGGC; CXCR4-F1 5'-A AAGTACCCAGTTGGCCACGGC; CXCR4-R1 5'-GCA TGACGGACAAGTACAGGCT; GAPDH-F2 5'-TCA TTTCTCGTATGACAAACGA; GAPDH-R2 5'-TCA TACATGCGCA ACTGTAGGAG; Reactions were performed in triplicates, DDct method was used to analyze data [95].

Migration assays

Migration assays were carried out in a 24-well transwell system equipped with porous (8 μm) polycarbonate membranes. 2 × 10⁶ MB cells were resuspended in 600 μl of growth medium supplemented with 1% FBS and plated into the lower chamber of the transwell system; 5.0 × 10⁵ BMSC cells were resuspended in 200 mlk of growth medium supplemented with 1% FBS and plated into Transwell inserts which were then placed into another transwell system with the lower chamber filled with 600 μl of serum-free medium. After 24 hours the cells on the inserts or in lower chambers were transfected as indicated, 6 hours after the transfection the media was changed and the inserts with BMSC, were placed into the wells with MB cells and incubated at 37 °C for 24 h. When indicated, CXCR4 (Abcam, #ab10403) or SDF1 (CXCL12) (Abcam, #ab9797) antibodies were added to the medium at 10 mkg/ml and 4 mkg/ml concentrations respectively. The inserts were then discarded, and upper sides of the filters were swabbed to remove the cells that did not cross the membrane. The cells present on the lower side of the filters were then fixed in 4 % paraformaldehyde, stained with DAPI and the counted under the microscope. All the experiments were performed in duplicate. The following control antibodies were used: rabbit IgG control (AB-105-C, R&D systems) and mouse IgG2b isotype control (MAB004, R&D systems).

SDF-1α ELISA assay

3 × 10⁶ MB cells were plated on 10 cm dish and after 24 h were transfected with 8 μg of plasmid DNA using JetPEI as instructed by the producer (Polyplus transfection), ratio plasmid:JetPEI was 1:2; medium was changed 24 h after the transfection. To quantify secreted CXCL12, the medium was collected 48 h after the transfection, centrifuged at 10 000 rpm for 10 min and concentrated 20 times using a 15 ml spin concentrators (5 KDa MWCO) (Agilent Technologies). To quantify intracellular CXCL12, whole cell lysates were prepared in 500 μl of RIPA buffer and diluted 10 times prior to analysis. Samples were analyzed in triplicates using human SDF 1α ELISA Kit (Abcam #ab100637).

ACKNOWLEDGMENTS

The research has been supported by the MEGAFSHD grant from the Association Française contre les Myopathies (AFM) to YSV. PD was supported by Association de Recherche Contre le Cancer (ARC), and the Amis FSH association. The work of EK was partly conducted in the frame of the IDB RAS government program of basic research № 0108-2014-0004.
CONFLICTS OF INTEREST

None.

REFERENCES


